POSEIDA THERAPEUTICS INC's ticker is PSTX and the CUSIP is 73730P108. A total of 53 filers reported holding POSEIDA THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,029,081 | +35.4% | 13,037,429 | +0.2% | 0.00% | +50.0% |
| Q2 2023 | $22,908,742 | -71.3% | 13,016,331 | -49.9% | 0.00% | -50.0% |
| Q1 2023 | $79,951,132 | +17.0% | 25,958,160 | +101.3% | 0.00% | -42.9% |
| Q4 2022 | $68,329,757 | +54.3% | 12,892,407 | +2.7% | 0.01% | +40.0% |
| Q3 2022 | $44,298,000 | +82.6% | 12,549,052 | +33.4% | 0.01% | +150.0% |
| Q2 2022 | $24,266,000 | -42.3% | 9,405,708 | +0.3% | 0.00% | -33.3% |
| Q1 2022 | $42,033,000 | -34.2% | 9,382,154 | +0.1% | 0.00% | -40.0% |
| Q4 2021 | $63,850,000 | -6.3% | 9,375,941 | +0.3% | 0.01% | 0.0% |
| Q3 2021 | $68,167,000 | -27.0% | 9,350,789 | +0.3% | 0.01% | -28.6% |
| Q2 2021 | $93,418,000 | +5.0% | 9,323,206 | +0.1% | 0.01% | -12.5% |
| Q1 2021 | $88,970,000 | -12.0% | 9,316,225 | +0.5% | 0.01% | -11.1% |
| Q4 2020 | $101,065,000 | +31.4% | 9,273,001 | +0.0% | 0.01% | +12.5% |
| Q3 2020 | $76,914,000 | – | 9,272,926 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,043,267 | $7,605,000 | 1.52% |
| Privium Fund Management (UK) Ltd | 48,470 | $353,000 | 0.38% |
| Pentwater Capital Management LP | 4,967,227 | $36,211,000 | 0.37% |
| J. Goldman & Co LP | 301,391 | $2,197,000 | 0.11% |
| Perceptive Advisors | 787,745 | $5,743,000 | 0.08% |
| KNOTT DAVID M | 29,566 | $216,000 | 0.08% |
| Virtus ETF Advisers LLC | 23,082 | $168,000 | 0.07% |
| Altium Capital Management LP | 32,238 | $235,000 | 0.06% |
| Advisory Services Network, LLC | 268,290 | $1,956,000 | 0.06% |
| MCF Advisors LLC | 66,185 | $482,000 | 0.05% |